研究者データベース


フリーワードで探す

全文検索となっています

李 政樹リ マサキ

所属部署医学研究科血液・腫瘍内科学分野
職名講師
メールアドレスrrmasakiybb.ne.jp
ホームページURLhttp://ncu-ketsuekishuyo.jp/
生年月日
Last Updated :2019/07/06

研究者基本情報

基本情報

    ORCID ID:0000-0002-9617-486X

研究活動情報

研究キーワード

    分子標的薬, 多発性骨髄腫, 耐性, 小胞体ストレス

論文

  • Cyclin-dependent kinase 9 as a potential specific molecular target in NK cell leukemia/lymphoma., Kinoshita S, Ishida T, Ito A, Narita T, Masaki A, Suzuki S, Yoshida T, Ri M, Kusumoto S, Komatsu H, Shimizu N, Inagaki H, Kuroda T, Scholz A, Ueda R, Sanda T, Iida S, Haematologica,   2018年08月, 査読有り
  • Human T-cell lymphotropic/leukemia virus type 1 (HTLV-1) Tax-specific T-cell exhaustion in HTLV-1-infected individuals., Masaki A, Ishida T, Suzuki S, Ito A, Narita T, Kinoshita S, Ri M, Kusumoto S, Komatsu H, Inagaki H, Ueda R, Iida S, Cancer science, 109, (8) 2383 - 2390,   2018年08月, 査読有り
  • Potent antitumor effect of combination therapy with sub-optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma., Kinoshita S, Ri M, Kanamori T, Aoki S, Yoshida T, Narita T, Totani H, Ito A, Kusumoto S, Ishida T, Komatsu H, Iida S, Oncology letters, 15, (6) 9450 - 9456,   2018年06月, 査読有り
  • A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple Myeloma., Ri M, Suzuki K, Iida S, Hatake K, Chou T, Taniwaki M, Watanabe N, Tsukamoto T, Internal medicine (Tokyo, Japan), 57, (7) 939 - 946,   2018年04月, 査読有り
  • Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunits., Yoshida T, Ri M, Kanamori T, Aoki S, Ashour R, Kinoshita S, Narita T, Totani H, Masaki A, Ito A, Kusumoto S, Ishida T, Komatsu H, Kitahata S, Chiba T, Ichikawa S, Iida S, Oncotarget, 9, (11) 9975 - 9991,   2018年02月, 査読有り
  • Clinical significance of tryptophan catabolism in Hodgkin lymphoma., Masaki A, Ishida T, Maeda Y, Ito A, Suzuki S, Narita T, Kinoshita S, Takino H, Yoshida T, Ri M, Kusumoto S, Komatsu H, Inagaki H, Ueda R, Choi I, Suehiro Y, Iida S, Cancer science, 109, (1) 74 - 83,   2018年01月, 査読有り
  • [Role of novel proteasome inhibitors in the treatment of relapsed/refractory multiple myeloma]., Ri M, [Rinsho ketsueki] The Japanese journal of clinical hematology, 59, (10) 2162 - 2168,   2018年, 査読有り
  • Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma., Yoshida T, Ri M, Kinoshita S, Narita T, Totani H, Ashour R, Ito A, Kusumoto S, Ishida T, Komatsu H, Iida S, PloS one, 13, (5) ,   2018年, 査読有り
  • Anaplastic multiple myeloma: possible limitations of conventional chemotherapy for long-term remission., Ichikawa S, Fukuhara N, Hatta S, Himuro M, Nasu K, Ono K, Okitsu Y, Kobayashi M, Onishi Y, Ri M, Ichinohasama R, Harigae H, Journal of clinical and experimental hematopathology : JCEH, 58, (1) 39 - 42,   2018年, 査読有り
  • [Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance mimicking POEMS syndrome]., Kanamori T, Kusumoto S, Okita K, Hagiwara S, Kato C, Nakashima T, Murakami S, Narita T, Ito A, Ri M, Ishida T, Komatsu H, Matsukawa N, Iida S, [Rinsho ketsueki] The Japanese journal of clinical hematology, 59, (2) 161 - 166,   2018年, 査読有り
  • Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study., Iida S, Suzuki K, Kusumoto S, Ri M, Tsukada N, Abe Y, Aoki M, Inagaki M, International journal of hematology, 106, (4) 541 - 551,   2017年10月, 査読有り
  • Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma., Ri M, Matsue K, Sunami K, Shimazaki C, Hayashi A, Sunaga Y, Sasaki T, Suzuki K, International journal of hematology, 106, (4) 562 - 572,   2017年10月, 査読有り
  • Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma., Narita T, Ishida T, Ito A, Masaki A, Kinoshita S, Suzuki S, Takino H, Yoshida T, Ri M, Kusumoto S, Komatsu H, Imada K, Tanaka Y, Takaori-Kondo A, Inagaki H, Scholz A, Lienau P, Kuroda T, Ueda R, Iida S, Blood, 130, (9) 1114 - 1124,   2017年08月, 査読有り
  • Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple myeloma., Tatekawa S, Chinen Y, Ri M, Narita T, Shimura Y, Matsumura-Kimoto Y, Tsukamoto T, Kobayashi T, Kawata E, Uoshima N, Taki T, Taniwaki M, Handa H, Iida S, Kuroda J, British journal of haematology, 178, (4) 534 - 546,   2017年08月, 査読有り
  • Novel monitoring of hepatitis B reactivation based on ultra-high sensitive hepatitis B surface antigen assay., Shinkai N, Kusumoto S, Murakami S, Ogawa S, Ri M, Matsui T, Tamori A, Toyoda H, Ishida T, Iida S, Tanaka Y, Liver international : official journal of the International Association for the Study of the Liver, 37, (8) 1138 - 1147,   2017年08月, 査読有り
  • Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan., Suzuki K, Ri M, Chou T, Sugiura I, Takezako N, Sunami K, Ishida T, Izumi T, Ozaki S, Shumiya Y, Ota K, Iida S, Cancer science, 108, (3) 461 - 468,   2017年03月, 査読有り
  • The value of serum Wisteria floribunda agglutinin-positive human Mac-2-binding protein as a predictive marker for hepatitis C virus-related complications after systemic chemotherapy., Totani H, Kusumoto S, Tanaka Y, Suzuki N, Hagiwara S, Kinoshita S, Iio E, Ito A, Ri M, Ishida T, Komatsu H, Iida S, International journal of hematology, 104, (3) 384 - 391,   2016年09月, 査読有り
  • Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma., Ri M, International journal of hematology, 104, (3) 273 - 280,   2016年09月, 査読有り
  • Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy., Ri M, [Rinsho ketsueki] The Japanese journal of clinical hematology, 57, (5) 537 - 545,   2016年05月, 査読有り
  • Design, Synthesis, and Biological Activity of Isosyringolin A., Kitahata S, Chiba T, Yoshida T, Ri M, Iida S, Matsuda A, Ichikawa S, Organic letters, 18, (9) 2312 - 2315,   2016年05月, 査読有り
  • Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma., Totani H, Ri M, Kato C, Nakashima T, Suzuki N, Hagiwara S, Kanamori T, Murakami S, Masuda A, Kinoshita S, Yoshida T, Narita T, Ito A, Kusumoto S, Ishida T, Komatsu H, Iida S, International journal of hematology, 103, (3) 316 - 321,   2016年03月, 査読有り
  • Labial salivary gland biopsy for diagnosing immunoglobulin light chain amyloidosis: a retrospective analysis., Suzuki T, Kusumoto S, Yamashita T, Masuda A, Kinoshita S, Yoshida T, Takami-Mori F, Takino H, Ito A, Ri M, Ishida T, Komatsu H, Ueda M, Ando Y, Inagaki H, Iida S, Annals of hematology, 95, (2) 279 - 285,   2016年01月, 査読有り
  • Long-term follow-up results of a phase I/II study of melphalan, prednisolone and bortezomib in Japanese transplant-ineligible multiple myeloma patients (JPN-102)., Ogiya D, Shibayama H, Nakatani E, Ando K, Suzuki K, Kuroda Y, Uchida T, Maruyama D, Matsumoto M, Matsue K, Iida S, Terui Y, Ri M, Chou T, Aotsuka N, Tabata S, Konishi J, Ohashi K, Shinagawa A, Sugiura I, Kuroda J, Miyamoto T, Ogura M, Tobinai K, Kanakura Y, Hotta T, [Rinsho ketsueki] The Japanese journal of clinical hematology, 57, (11) 2311 - 2318,   2016年, 査読有り
  • [Prognostic significance of tryptophan catabolism in adult T-cell leukemia/lymphoma]., Masaki A, Ishida T, Maeda Y, Suzuki S, Ito A, Takino H, Totani H, Yoshida T, Kinoshita S, Ogura H, Narita T, Ri M, Kusumoto S, Inagaki A, Komatsu H, Niimi A, Ueda R, Utsunomiya A, Inagaki H, Iida S, [Rinsho ketsueki] The Japanese journal of clinical hematology, 56, (11) 2295 - 2304,   2015年11月, 査読有り
  • Overexpression of salivary-type amylase reduces the sensitivity to bortezomib in multiple myeloma cells., Mizuno S, Hanamura I, Ota A, Karnan S, Narita T, Ri M, Mizutani M, Goto M, Gotou M, Tsunekawa N, Shikami M, Iida S, Hosokawa Y, Miwa H, Ueda R, Nitta M, Takami A, International journal of hematology, 102, (5) 569 - 578,   2015年11月, 査読有り
  • [Transplant-Related Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Busulfan-Based Reduced-Intensity Conditioning - A Retrospective Analysis in a Single Institution]., Yoshida T, Kusumoto S, Masuda A, Totani H, Narita T, Masaki A, Ito A, Ri M, Ishida T, Komatsu H, Iida S, Gan to kagaku ryoho. Cancer & chemotherapy, 42, (6) 719 - 724,   2015年06月, 査読有り
  • Prognostic Significance of Tryptophan Catabolism in Adult T-cell Leukemia/Lymphoma., Masaki A, Ishida T, Maeda Y, Suzuki S, Ito A, Takino H, Ogura H, Totani H, Yoshida T, Kinoshita S, Narita T, Ri M, Kusumoto S, Inagaki A, Komatsu H, Niimi A, Ueda R, Utsunomiya A, Inagaki H, Iida S, Clinical cancer research : an official journal of the American Association for Cancer Research, 21, (12) 2830 - 2839,   2015年06月, 査読有り
  • Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia-lymphoma patients with resolved HBV infection following systemic chemotherapy., Totani H, Kusumoto S, Ishida T, Masuda A, Yoshida T, Ito A, Ri M, Komatsu H, Murakami S, Mizokami M, Ueda R, Niimi A, Inagaki H, Tanaka Y, Iida S, International journal of hematology, 101, (4) 398 - 404,   2015年04月, 査読有り
  • TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities., Sagawa M, Tabayashi T, Kimura Y, Tomikawa T, Nemoto-Anan T, Watanabe R, Tokuhira M, Ri M, Hashimoto Y, Iida S, Kizaki M, Cancer science, 106, (4) 438 - 446,   2015年04月, 査読有り
  • Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells., Wada N, Kawano Y, Fujiwara S, Kikukawa Y, Okuno Y, Tasaki M, Ueda M, Ando Y, Yoshinaga K, Ri M, Iida S, Nakashima T, Shiotsu Y, Mitsuya H, Hata H, International journal of oncology, 46, (3) 963 - 972,   2015年03月, 査読有り
  • Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma., Watanabe T, Mitsuhashi M, Sagawa M, Ri M, Suzuki K, Abe M, Ohmachi K, Nakagawa Y, Nakamura S, Chosa M, Iida S, Kizaki M, PloS one, 10, (6) ,   2015年, 査読有り
  • Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma., Chinen Y, Kuroda J, Shimura Y, Nagoshi H, Kiyota M, Yamamoto-Sugitani M, Mizutani S, Sakamoto N, Ri M, Kawata E, Kobayashi T, Matsumoto Y, Horiike S, Iida S, Taniwaki M, Cancer research, 74, (24) 7418 - 7429,   2014年12月, 査読有り
  • Prognostic impact of microRNA-145 down-regulation in adult T-cell leukemia/lymphoma., Xia H, Yamada S, Aoyama M, Sato F, Masaki A, Ge Y, Ri M, Ishida T, Ueda R, Utsunomiya A, Asai K, Inagaki H, Human pathology, 45, (6) 1192 - 1198,   2014年06月, 査読有り
  • [Determinants of sensitivity to proteasome inhibitors and strategies to overcome acquired resistance to bortezomib in multiple myeloma]., Iida S, Ri M, [Rinsho ketsueki] The Japanese journal of clinical hematology, 55, (3) 304 - 310,   2014年03月, 査読有り
  • Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors., Suzuki T, Muto N, Bando M, Itoh Y, Masaki A, Ri M, Ota Y, Nakagawa H, Iida S, Shirahige K, Miyata N, ChemMedChem, 9, (3) 657 - 664,   2014年03月, 査読有り
  • Antitumor effects of bevacizumab in a microenvironment-dependent human adult T-cell leukemia/lymphoma mouse model., Mori F, Ishida T, Ito A, Sato F, Masaki A, Narita T, Suzuki S, Yamada T, Takino H, Ri M, Kusumoto S, Komatsu H, Hishizawa M, Imada K, Takaori-Kondo A, Niimi A, Ueda R, Inagaki H, Iida S, European journal of haematology, 92, (3) 219 - 228,   2014年03月, 査読有り
  • HTLV-1 bZIP factor-specific CD4 T cell responses in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantation., Narita T, Ishida T, Masaki A, Suzuki S, Ito A, Mori F, Yamada T, Ri M, Kusumoto S, Komatsu H, Miyazaki Y, Takatsuka Y, Utsunomiya A, Niimi A, Iida S, Ueda R, Journal of immunology (Baltimore, Md. : 1950), 192, (3) 940 - 947,   2014年02月, 査読有り
  • Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myeloma., Inagaki A, Tajima E, Uranishi M, Totani H, Asao Y, Ogura H, Masaki A, Yoshida T, Mori F, Ito A, Yano H, Ri M, Kayukawa S, Kataoka T, Kusumoto S, Ishida T, Hayami Y, Hanamura I, Komatsu H, Inagaki H, Matsuda Y, Ueda R, Iida S, Leukemia research, 37, (12) 1648 - 1655,   2013年12月, 査読有り
  • [Myeloma therapy (3) Trends in development of new drugs]., Ri M, Iida S, [Rinsho ketsueki] The Japanese journal of clinical hematology, 54, (8) 715 - 718,   2013年08月, 査読有り
  • Autologous Tax-specific CTL therapy in a primary adult T cell leukemia/lymphoma cell-bearing NOD/Shi-scid, IL-2Rγnull mouse model., Masaki A, Ishida T, Suzuki S, Ito A, Mori F, Sato F, Narita T, Yamada T, Ri M, Kusumoto S, Komatsu H, Tanaka Y, Niimi A, Inagaki H, Iida S, Ueda R, Journal of immunology (Baltimore, Md. : 1950), 191, (1) 135 - 144,   2013年07月, 査読有り
  • Successful salvage therapy using lenalidomide in a patient with relapsed multiple myeloma after allogeneic hematopoietic stem cell transplantation., Suzuki T, Kusumoto S, Yoshida T, Mori F, Ito A, Ri M, Ishida T, Komatsu H, Niimi A, Iida S, International journal of hematology, 97, (4) 540 - 543,   2013年04月, 査読有り
  • Angioimmunoblastic T-cell lymphoma mice model., Sato F, Ishida T, Ito A, Mori F, Masaki A, Takino H, Narita T, Ri M, Kusumoto S, Suzuki S, Komatsu H, Niimi A, Ueda R, Inagaki H, Iida S, Leukemia research, 37, (1) 21 - 27,   2013年01月, 査読有り
  • RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma., Shimura Y, Kuroda J, Ri M, Nagoshi H, Yamamoto-Sugitani M, Kobayashi T, Kiyota M, Nakayama R, Mizutani S, Chinen Y, Sakamoto N, Matsumoto Y, Horiike S, Shiotsu Y, Iida S, Taniwaki M, Molecular cancer therapeutics, 11, (12) 2600 - 2609,   2012年12月, 査読有り
  • Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries., Suzuki T, Ota Y, Ri M, Bando M, Gotoh A, Itoh Y, Tsumoto H, Tatum PR, Mizukami T, Nakagawa H, Iida S, Ueda R, Shirahige K, Miyata N, Journal of medicinal chemistry, 55, (22) 9562 - 9575,   2012年11月, 査読有り
  • Tax is a potential molecular target for immunotherapy of adult T-cell leukemia/lymphoma., Suzuki S, Masaki A, Ishida T, Ito A, Mori F, Sato F, Narita T, Ri M, Kusumoto S, Komatsu H, Fukumori Y, Nishikawa H, Tanaka Y, Niimi A, Inagaki H, Iida S, Ueda R, Cancer science, 103, (10) 1764 - 1773,   2012年10月, 査読有り
  • Forkhead box P1 overexpression and its clinicopathologic significance in peripheral T-cell lymphoma, not otherwise specified., Yamada S, Sato F, Xia H, Takino H, Kominato S, Ri M, Ishida T, Iida S, Inagaki H, Yamada K, Human pathology, 43, (8) 1322 - 1327,   2012年08月, 査読有り
  • A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL-2Rγ(null) mouse lymphoma model., Sato F, Ito A, Ishida T, Mori F, Takino H, Inagaki A, Ri M, Kusumoto S, Komatsu H, Iida S, Okada N, Inagaki H, Ueda R, Cancer immunology, immunotherapy : CII, 59, (12) 1791 - 1800,   2010年12月, 査読有り
  • Reactivation of hepatitis B virus in HBsAg-negative patients with multiple myeloma: two case reports., Yoshida T, Kusumoto S, Inagaki A, Mori F, Ito A, Ri M, Ishida T, Komatsu H, Iida S, Sugauchi F, Tanaka Y, Mizokami M, Ueda R, International journal of hematology, 91, (5) 844 - 849,   2010年06月, 査読有り
  • [Anti-CCR4 monoclonal antibody as a novel therapy for advanced mycosis fungoides and Sézary syndrome]., Yano H, Ishida T, Inagaki A, Ishii T, Ri M, Ito A, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R, [Rinsho ketsueki] The Japanese journal of clinical hematology, 50, (12) 1671 - 1678,   2009年12月, 査読有り
  • Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo., Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, Yano H, Inagaki A, Suzuki S, Takino H, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R, Journal of immunology (Baltimore, Md. : 1950), 183, (7) 4782 - 4791,   2009年10月, 査読有り
  • The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity., Ding J, Komatsu H, Iida S, Yano H, Kusumoto S, Inagaki A, Mori F, Ri M, Ito A, Wakita A, Ishida T, Nitta M, Ueda R, Blood, 114, (15) 3325 - 3328,   2009年10月, 査読有り
  • Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model., Ito A, Ishida T, Yano H, Inagaki A, Suzuki S, Sato F, Takino H, Mori F, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R, Cancer immunology, immunotherapy : CII, 58, (8) 1195 - 1206,   2009年08月, 査読有り
  • Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC., Inagaki A, Ishida T, Yano H, Ishii T, Kusumoto S, Ito A, Ri M, Mori F, Ding J, Komatsu H, Iida S, Ueda R, International journal of cancer, 125, (1) 212 - 221,   2009年07月, 査読有り
  • Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1., Ri M, Iida S, Ishida T, Ito A, Yano H, Inagaki A, Ding J, Kusumoto S, Komatsu H, Utsunomiya A, Ueda R, Cancer science, 100, (2) 341 - 348,   2009年02月, 査読有り
  • Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma., Yano H, Kayukawa S, Iida S, Nakagawa C, Oguri T, Sanda T, Ding J, Mori F, Ito A, Ri M, Inagaki A, Kusumoto S, Ishida T, Komatsu H, Inagaki H, Suzuki A, Ueda R, Cancer science, 99, (11) 2309 - 2314,   2008年11月, 査読有り
  • [Histopathological findings of pulmonary complications in 16 patients who received allogeneic hematopoietic stem cell transplants]., Iida H, Ri M, Niimi K, Harada T, Sao H, [Rinsho ketsueki] The Japanese journal of clinical hematology, 46, (12) 1273 - 1278,   2005年12月, 査読有り


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.